A new Video compiled in Australia shows how Exon Skipping is moving forward as one of the leading potential therapies for Duchenne. It briefly describes at a high level what the therapy includes and the current position of one of the trials happening in the UK and this trials next steps.

Recently news of the current UK trial was positive with AVI-4658, currently being evaluated in an ongoing Phase 1b/2 clinical trial at two sites in the United Kingdom and has been generally well tolerated to date in all patients dosed up to 20mg/kg for 12 weeks. More information from the MDEX Consortium